JP2008514588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514588A5 JP2008514588A5 JP2007533418A JP2007533418A JP2008514588A5 JP 2008514588 A5 JP2008514588 A5 JP 2008514588A5 JP 2007533418 A JP2007533418 A JP 2007533418A JP 2007533418 A JP2007533418 A JP 2007533418A JP 2008514588 A5 JP2008514588 A5 JP 2008514588A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- contrast agent
- leu
- trp
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (5)
- 次の式IaのuPARターゲティング造影剤。
Z1−W1−X0−X1−Phe−X2−X3−X4−Leu−Trp−X5−X6−W2−Z2(Ia)
式中、
X0は1〜5個のアミノ酸を表し、
X1、X2、X3、X4及びX5は独立に1つのアミノ酸を表し、
Pheはフェニルアラニンを表し、
Leuはロイシンを表し、
Trpはトリプトファンを表し、
X6は0〜5個のアミノ酸を表すか又は次の式(Ib)であり、
β−Ala−Lys(Z1−W1−X0−X1−Phe−X2−X3−X4−Leu−Trp−X5)(Ib)
式中、記号は式Iaで定義した通りであり、
β−Alaはβアラニンを表し、
Lysはリシンを表し、
式Ibのβ−Alaは式IaのX5に結合しており、
W1及びW2は同一又は異なる部分であって、各々スペーサー、バイオモディファイヤーであるか或いは存在せず、Z1又はZ2の少なくとも一方が存在していて画像診断法で直接又は間接的に検出できる造影性部分を表す。 - ペプチド配列Z1−W1−X0−Cha−Phe−Ser−Arg−Tyr−Leu−Trp−Ser−X6−W2−Z2を含む、請求項1記載の造影剤。
式中、Chaはシクロヘキシルアラニンを表し、Serはセリンを表し、Argはアルギニンを表し、Tyrはチロシンを表し、他のすべての記号は既に定義した通りである。 - W1及びW2の少なくとも一方が1〜10単位の単分散PEG構成単位又は1〜10個のアミノ酸残基を含む、請求項1又は請求項2記載の造影剤。
- Z1及びZ2の少なくとも一方が放射線、SPECT、PET、X線、MR、超音波又は光学イメージングで検出できる部分を含むインビボ診断用の造影性部分を表す、請求項1乃至請求項3のいずれか1項記載の造影剤。
- 請求項1乃至請求項4のいずれか1項記載の造影剤を、薬学的に許容される1種以上の補助剤、賦形剤又は希釈剤と共に含んでなる医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20044139 | 2004-09-29 | ||
NO20044139 | 2004-09-29 | ||
PCT/NO2005/000362 WO2006036071A2 (en) | 2004-09-29 | 2005-09-28 | Urokinase plasminogen activator receptor targeted contrast agent |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008514588A JP2008514588A (ja) | 2008-05-08 |
JP2008514588A5 true JP2008514588A5 (ja) | 2008-11-06 |
JP5122962B2 JP5122962B2 (ja) | 2013-01-16 |
Family
ID=35930012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007533418A Expired - Fee Related JP5122962B2 (ja) | 2004-09-29 | 2005-09-28 | uPARターゲティング造影剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8568689B1 (ja) |
EP (1) | EP1796733A2 (ja) |
JP (1) | JP5122962B2 (ja) |
KR (1) | KR101248350B1 (ja) |
CN (1) | CN101065152A (ja) |
AU (1) | AU2005287934B2 (ja) |
BR (1) | BRPI0516168A (ja) |
CA (1) | CA2580464A1 (ja) |
MX (1) | MX2007003750A (ja) |
RU (1) | RU2394837C2 (ja) |
WO (1) | WO2006036071A2 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070190068A1 (en) * | 2005-10-10 | 2007-08-16 | Richard Hart | uPAR-binding molecule-drug conjugates and uses thereof |
EP2091570A1 (en) * | 2006-12-20 | 2009-08-26 | GE Healthcare AS | Contrast agents |
GB0718967D0 (en) * | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Peptide imaging agents |
GB0718957D0 (en) * | 2007-09-28 | 2007-11-07 | Ge Healthcare Ltd | Optical imaging agents |
CN103108659A (zh) * | 2010-07-27 | 2013-05-15 | 通用电气健康护理有限公司 | 放射性药物组合物 |
CA2905172C (en) * | 2012-05-08 | 2021-07-20 | Andreas Kjaer | 177-lu labeled peptide for site-specific upar-targeting |
CA2903261C (en) | 2012-12-03 | 2021-03-09 | Curasight Aps | Positron emitting radionuclide labeled peptides for human upar pet imaging |
US20210138090A1 (en) * | 2014-09-17 | 2021-05-13 | Fluoguide A/S | uPAR targeting peptide for use in peroperative optical imaging of invasive cancer |
AU2015317444B2 (en) * | 2014-09-17 | 2020-07-16 | Fluoguide A/S | uPAR targeting peptide for use in peroperative optical imaging of invasive cancer |
ES2683554T3 (es) * | 2015-06-03 | 2018-09-26 | Surgimab S.A.S. | Conjugados fluorescentes |
WO2019169342A1 (en) | 2018-03-01 | 2019-09-06 | Trigemina, Inc. | Labeled oxytocin and method of manufacture and use |
US20220257799A1 (en) * | 2019-07-16 | 2022-08-18 | Fluoguide A/S | A receptor-targeting conjugate with an effective pharmacokinetic profile |
JP2022544647A (ja) * | 2019-07-16 | 2022-10-20 | リグスホスピタレット | ウロキナーゼプラスミノーゲン活性化因子受容体標的化ペプチド |
CA3200503A1 (en) | 2020-12-01 | 2022-06-09 | Andreas Kjaer | Urokinase plasminogen activator receptor targeted radiolabeled peptide conjugates |
US20240066142A1 (en) * | 2021-01-15 | 2024-02-29 | Fluoguide A/S | A upar (urokinase plasminogen activator receptor)-targeting conjugate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120765A (en) * | 1993-04-02 | 2000-09-19 | Shiseido Co. Ltd. | Urokinase plasminogen activator fragments |
US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
US6277818B1 (en) * | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
GB9705521D0 (en) | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
AR020101A1 (es) | 1998-07-01 | 2002-04-10 | Cancerforskingsfonden Af 1989 | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. |
US6896870B1 (en) * | 1999-10-01 | 2005-05-24 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting uPA and uPAR |
AU780730B2 (en) * | 1999-10-01 | 2005-04-14 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting uPA and uPAR |
US7763234B2 (en) | 2004-03-04 | 2010-07-27 | Ge Healthcare As | Pharmaceutical compounds |
-
2005
- 2005-09-28 BR BRPI0516168-1A patent/BRPI0516168A/pt not_active IP Right Cessation
- 2005-09-28 MX MX2007003750A patent/MX2007003750A/es active IP Right Grant
- 2005-09-28 EP EP05788552A patent/EP1796733A2/en not_active Withdrawn
- 2005-09-28 JP JP2007533418A patent/JP5122962B2/ja not_active Expired - Fee Related
- 2005-09-28 CA CA002580464A patent/CA2580464A1/en not_active Abandoned
- 2005-09-28 WO PCT/NO2005/000362 patent/WO2006036071A2/en active Application Filing
- 2005-09-28 RU RU2007111467/04A patent/RU2394837C2/ru not_active IP Right Cessation
- 2005-09-28 CN CNA2005800408838A patent/CN101065152A/zh active Pending
- 2005-09-28 US US11/576,193 patent/US8568689B1/en not_active Expired - Fee Related
- 2005-09-28 AU AU2005287934A patent/AU2005287934B2/en not_active Ceased
- 2005-09-28 KR KR1020077007004A patent/KR101248350B1/ko not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008514588A5 (ja) | ||
RU2007111467A (ru) | Контрастный агент, нацеленный на рецептор урокиназного активатора плазминогена | |
JP2011518179A5 (ja) | ||
JP2020502051A5 (ja) | ||
EP0746340B1 (en) | Peptide-chelator conjugates | |
JP2007535493A5 (ja) | ||
JPH10502931A (ja) | ペプチド誘導の放射性核種キレート化剤 | |
JP2013500990A5 (ja) | ||
CA2405469A1 (en) | Integrin binding peptide derivatives | |
JP2012518035A5 (ja) | ||
JP7295871B2 (ja) | 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用 | |
JP2021520346A (ja) | 新規glp−1類似体 | |
JP2013531660A5 (ja) | ||
RU2013146690A (ru) | Циклические пептиды с антинеопластической и антиангионенной активностью | |
CN103547291A (zh) | 锝标记的肽 | |
DE602008004897D1 (de) | Verbindungen zur diagnose von mit der vcam-expression assoziierten krankheiten | |
US7763234B2 (en) | Pharmaceutical compounds | |
KR20230051583A (ko) | Crf2 수용체 작용제 및 치료에서의 이의 용도 | |
JP2015507620A (ja) | 患者選別方法 | |
JP2007526300A5 (ja) | ||
ES2387435B1 (es) | Uso de heptapéptidos para el control de la hipertensión | |
JP2024520234A (ja) | Psd-95阻害剤及びその使用 | |
JP2005082489A (ja) | 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド | |
WO2003033030A1 (en) | Pacap compositions and methods for tumor imaging and therapy | |
EP0835123A1 (en) | Aminopeptidase p inhibitors and uses thereof |